Literature DB >> 15179127

Transfusion of the injured patient: proceed with caution.

Christopher C Silliman1, Ernest E Moore, Jeffrey L Johnson, Ricardo J Gonzalez, Walter L Biffl.   

Abstract

Transfusion of the injured patient with packed red blood cells (PRBCs) is a dynamic process requiring vigilance during the acute resuscitative and recovery phases postinjury. Although adverse events have been reported in 2% to 10% of injured patients, the advent of new detection techniques for viral pathogens has markedly decreased the risk of infectious transmission. However, transfusions are strongly associated with immunosuppression in the host, which may occur days after the initial injury and may lead to bacterial infections. Conversely, early transfusion of stored PRBCs, > 6 units in the first 12 h postinjury, contributes to an early state of hyperinflammation that is a strong, independent predictor of multiple organ failure (MOF) in those patients with intermediate injury severity scores. The roles of prestorage leukoreduction are also reviewed with respect to the promotion of both immunosuppression and hyperinflammation. We further summarize studies with hemoglobin substitutes, whose use may obviate many of the untoward events of transfusion and promise to lead to better outcomes for injured patients.

Entities:  

Mesh:

Year:  2004        PMID: 15179127     DOI: 10.1097/00024382-200404000-00001

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  24 in total

1.  New trends in resuscitation.

Authors:  Hasan B Alam; George C Velmahos
Journal:  Curr Probl Surg       Date:  2011-08       Impact factor: 1.909

2.  The role of NIGMS P50 sponsored team science in our understanding of multiple organ failure.

Authors:  Frederick A Moore; Ernest E Moore; Timothy R Billiar; Yoram Vodovotz; Anirban Banerjee; Lyle L Moldawer
Journal:  J Trauma Acute Care Surg       Date:  2017-09       Impact factor: 3.313

Review 3.  Effect of processing and storage on red blood cell function in vivo.

Authors:  Allan Doctor; Phil Spinella
Journal:  Semin Perinatol       Date:  2012-08       Impact factor: 3.300

Review 4.  Postinjury Inflammation and Organ Dysfunction.

Authors:  Angela Sauaia; Frederick A Moore; Ernest E Moore
Journal:  Crit Care Clin       Date:  2017-01       Impact factor: 3.598

Review 5.  Transfusion Decision Making in Pediatric Critical Illness.

Authors:  Chris Markham; Sara Small; Peter Hovmand; Allan Doctor
Journal:  Pediatr Clin North Am       Date:  2017-10       Impact factor: 3.278

6.  Red blood cell transfusion in critically ill children is independently associated with increased mortality.

Authors:  Martin C J Kneyber; Mohammed I Hersi; Jos W R Twisk; Dick G Markhorst; Frans B Plötz
Journal:  Intensive Care Med       Date:  2007-06-16       Impact factor: 17.440

Review 7.  Resuscitation and transfusion principles for traumatic hemorrhagic shock.

Authors:  Philip C Spinella; John B Holcomb
Journal:  Blood Rev       Date:  2009-08-19       Impact factor: 8.250

8.  Outcome analysis of blood product transfusion in trauma patients: a prospective, risk-adjusted study.

Authors:  Grant V Bochicchio; Lena Napolitano; Manjari Joshi; Kelly Bochicchio; Walter Meyer; Thomas M Scalea
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

9.  Experimental prestorage filtration removes antibodies and decreases lipids in RBC supernatants mitigating TRALI in vivo.

Authors:  Christopher C Silliman; Marguerite R Kelher; Samina Y Khan; Monica LaSarre; F Bernadette West; Kevin J Land; Barbara Mish; Linda Ceriano; Samuel Sowemimo-Coker
Journal:  Blood       Date:  2014-04-18       Impact factor: 22.113

10.  Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries.

Authors:  Philip C Spinella; Christopher L Carroll; Ilene Staff; Ronald Gross; Jacqueline Mc Quay; Lauren Keibel; Charles E Wade; John B Holcomb
Journal:  Crit Care       Date:  2009-09-22       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.